Ivermectine Substipharm (Ivermectin)

Ivermectin binds to glutamate‑gated chloride channels in the nerve and muscle cells of invertebrate parasites. This increases chloride ion flow, causing hyperpolarisation of the cell membrane, leading to paralysis and death of the parasite while sparing human cells that lack these channels.

The exact dose of Ivermectine Substipharm is set by the prescribing clinician based on the specific indication, patient weight, age, and any relevant comorbidities. Dosage regimens vary between diseases and are not standardized in this description.

Safety data for ivermectin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk. Breastfeeding mothers should discuss possible exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ivermectin offers a broad‑spectrum oral option for several neglected tropical diseases, often requiring fewer doses than alternatives such as albendazole or diethylcarbamazine. Its selective mechanism provides a favorable safety profile, though choice of therapy depends on local resistance patterns, disease severity and patient factors.

Ivermectine Substipharm should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture, light and excessive heat to maintain product stability.

The medication is taken orally, usually with a full glass of water. It may be administered with or without food, depending on the prescriber’s instructions. Patients should follow the exact dosing schedule provided by their healthcare professional.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, neurologic complications like seizures or altered consciousness, and visual disturbances. Any sudden or severe symptoms should prompt immediate medical evaluation.

Ivermectine Substipharm is contraindicated in patients with known hypersensitivity to ivermectin or any excipients in the formulation. Caution is advised for individuals with severe hepatic or renal impairment, and it should be avoided in pregnant women unless the benefit outweighs the risk.